Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib + Ravoxertinib in solid tumors
NCT02457793Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ravoxertinib in solid tumor (6 arms), sponsored by Genentech. Primary endpoints: Number of Participants With Dose-Limiting Toxicities, Percentage of Participants With at Least One Adverse Event up to 15 months and 3 more. Started Jun 2015; status: completed.
02
Drugs
ravoxertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02457793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457793.